The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
Jen Kates, Senior Vice President and Director of KFF’s Global Health & HIV Policy program presented “The End of the Public Health Emergency Declaration for COVID-19,” at the 2023 Preparedness Summit on April 24.
In response to the COVID-19 pandemic, the federal government declared numerous types of emergencies, Congress enacted several pieces of legislation, and various executive actions were taken and waivers issued, which established time-limited flexibilities and provisions designed to protect individuals and the health system during the pandemic. This resource provides a timeline identifying key health-related flexibilities and provisions specified by these various measures, the specific measure that determines their end date, and their end date.
With planning beginning for an eventual COVID-19 vaccine, one important consideration is making sure that distribution processes and outreach and communication strategies reach people of color. Analysis of seasonal flu vaccination rates provides some insight into the potential barriers and issues to be addressed as part of COVID-19 vaccination efforts.
This brief examines key policy challenges and issues related to distributing a COVID-19 vaccine in the U.S., including funding, supply and logistics, federal, state, and local authorities, insurance coverage, addressing racial and ethnic disparities, and communication and trust.
This analysis of flu vaccination rates across states and across groups within each state highlights some of the challenges facing public health officials in ensuring most people receive a COVID-19 vaccine when one becomes available.
Approaching the end of 2020, two of the most pressing concerns facing the country are the long-standing issue of racial discrimination and the ongoing coronavirus pandemic. The issues have merged with the pandemic taking a disproportionate health and economic toll on people of color. As vaccines become available, prioritizing racial equity will become increasingly important for mitigating these disparities and preventing further widening of the going forward, especially as early polling indicates that people of…
Republicans and Black Americans are More Likely to Be Hesitant but Even Among These Groups Reasons Vary KFF has launched a new COVID-19 Vaccine Monitor to dive deeply into the public’s views about the vaccine and experiences getting it for as long as the pandemic lasts. First results released today show that Americans’ enthusiasm for getting a COVID-19 vaccination varies substantially across groups, with Republicans and Black Americans among those most hesitant. Overall, 71% of…
In the issue brief, KFF experts highlight the laws and regulations that are in place to ensure access to free COVID-19 vaccines for individuals regardless of their insurance status and explain how vaccine administration costs will be covered in private insurance, Medicare and Medicaid, and for the uninsured.
As the first doses of the new COVID-19 vaccine are delivered to health care workers and other early recipients, many Americans are eager to know not only when the vaccine will be available to them but also whether they will be able to get it at no cost. The answer is that providers are not allowed to charge patients who get the vaccine, at least during the public health emergency, KFF experts write in a…
New federal legislation will require most private health plans to cover testing for the coronavirus with no cost sharing. Some states have adopted similar requirements for insurers they regulate, and many private insurance companies will voluntarily expand coverage for testing. However, some private coverage will not be subject to these requirements. To date, fewer changes have been adopted or considered with respect to treatment for complications from the disease. This brief reviews current coverage standards…
© 2026 KFF